Volume : 13, Issue : 10, October – 2026
Title:
PHARMACOLOGICAL EVALUATION OF “ANTI-ATHEROSLEROTIC ACTIVITY OF TINOSPORA CORDIFOLIA IN ANIMAL MODEL”
Authors :
Deevan Paul Amaranath, Mahalakshmi Balan, Kavushik Mukundan
Abstract :
Neurotuberculosis is one of the most devastating forms of extrapulmonary tuberculosis, often resulting in severe neurological complications because of persistent neuroinflammation, oxidative stress, and poor drug penetration into the central nervous system. Although conventional anti-tubercular therapy has improved patient survival, its effectiveness is frequently compromised by therestrictive nature of the blood–brain barrier, prolonged treatment duration, systemic toxicity, and the increasing prevalence of drug resistant Mycobacterium tuberculosis. In recent years, cerebrospinal fluid has emerged as a promising therapeutic target owing to its central role in Central nervous system homeostasis and its ability to facilitate widespread drug distribution within the brain and spinal cord. Green-synthesized silver nanoparticles represent an innovative nanotherapeutic platform that combines environmentally sustainable synthesis with intrinsic antimicrobial, anti-inflammatory, antioxidant, and neuroprotective properties. This review provides a comprehensive overview of the molecular mechanisms underlying neuroinflammation and neurotuberculosis, highlights the therapeutic significance of Cerebrospinal fluid targeted drug delivery, and discusses the unique advantages of green-synthesized silver nanoparticles in overcoming Central nervous system delivery barriers. Furthermore, it examines their potential to suppress inflammatory signaling, preserve Blood Brain Barrier integrity, enhance anti-mycobacterial activity, and improve therapeutic outcomes. Finally, current translational challenges, safety considerations, and future clinical prospects are discussed, emphasizing the potential of Cerebrospinal fluid targeted green-synthesized silver nanoparticles as a promising next generation strategy for the treatment of neurotuberculosis and other neuroinflammatory disorders.
Keywords: Green-synthesized silver nanoparticles, Cerebrospinal fluid, Neurotuberculosis, Neuroinflammation, Central nervous system drug delivery.
Cite This Article:
Please cite this article in press D Paul Amaranath et al., Pharmacological Evaluation Of “Anti-Atheroslerotic Activity Of Tinospora Cordifolia In Animal Model.,. Indo Am. J. P. Sci, 2026; 13(10).
REFERENCES:
1. J Cantres-Fonseca O, Rodriguez-Cintrón W, Del Olmo-Arroyo F, Baez-Corujo S. Extra Pulmonary Tuberculosis: An Overview. In Intechopen; 2019.
2. Subedi RC, Bhatta M, Adhikari RB, Sedain G, Bastola S, Parajuli R, Yadav J, Pandey S, Paudel P, Paudel S, Dawadi K. Neurotuberculosis: Different facets of a single disease. Grande Medical Journal. 2025 Jul 21;5(1):56-74.
3. Gimenes Rodrigues M, Jose Da Rocha A, Rodrigues Masruha M, Soares Cianciarullo Minett T. Neurotuberculosis: An Overview. CNSAMC. 2011 Dec 1;11(4):246–260.
4. Wetzel SG, Kollmann T. Neurotuberculosis. In Springer Berlin Heidelberg; 2012. p. 59–66.
5. Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK. Central Nervous System Tuberculosis: Pathogenesis and Clinical Aspects. Clin Microbiol Rev. 2008 Apr 1;21(2):243–261.
6. Babkina II, Sergeeva SP, Gorbacheva LR. The Role of NF-κB in Neuroinflammation. Neurochem J. 2021 Apr 1;15(2):114–128.
7. Ablasser A, Dorhoi A. Inflammasome Activation and Function During Infection with Mycobacterium Tuberculosis. Current topics in microbiology and immunology. 2016 Jan 1;397:183–197.
8. Ahmed A. Treatment of Central Nervous System Tuberculosis. J Pediatr Infect Dis. 2018 Jan 15;13(02):141–152.
9. Kempker RR, Smith AG, Avaliani T, Gujabidze M, Bakuradze T, Sabanadze S, Avaliani Z, Collins JM, Blumberg HM, Alshaer MH, Peloquin CA. Cycloserine and linezolid for tuberculosis meningitis: pharmacokinetic evidence of potential usefulness. Clinical Infectious Diseases. 2022 Aug 15;75(4):682-9.
10. Kolloli A, Subbian S. Host-Directed Therapeutic Strategies for Tuberculosis. Front Med. 2017 Oct 18;4(10):171.
11. Han JR, Yang Y, Wu TW, Shi TT, Li W, Zou Y. A minimally-invasive method for serial cerebrospinal fluid collection and injection in rodents with high survival rates. bioRxiv (Cold Spring Harbor Laboratory). Cold Spring Harbor Laboratory; 2022.
12. Howaidy SH, Abdulijabar KH. The Biochemistry, Pathophysiology, And Clinical Importance of Cerebrospinal Fluid: A Review. ijmsdh. 2025 Nov 27;11(11):250–255.
13. Vinoothna B, Pan I. APPROACHES TO ENHANCE CNS DELIVERY OF DRUGS ACROSS THE BRAIN BARRIERS. IJEAST. 2020 May 10;04(12):347–353.
14. Ezeh CK, Eze CN, Dibua UME, Emencheta SC. A Systematic Review on Antituberculosis Drug Discovery and Antimycobacterial Potential of Biologically Synthesized Silver Nanoparticles: Overview and Future Perspectives. Infect Microb Dis. 2022 Nov 1;4(4):139–148.
15. Singh H, Desimone MF, Pandya S, Jasani S, George N, Adnan M, Aldarhami A, Bazaid AS, Alderhami SA. Revisiting the green synthesis of nanoparticles: uncovering influences of plant extracts as reducing agents for enhanced synthesis efficiency and its biomedical applications. International journal of nanomedicine. 2023 Dec 31:4727-50.
16. Gallardo-Toledo E, Velasco-Aguirre C, Kogan MJ. Inorganic Nanoparticles and Their Strategies to Enhance Brain Drug Delivery. In Springer Us; 2020. p. 149–172.
17. Khan AM, Korzeniowska B, Gorshkov V, Tahir M, Schrøder H, Skytte L, Rasmussen KL, Khandige S, Møller-Jensen J, Kjeldsen F. Silver nanoparticle-induced expression of proteins related to oxidative stress and neurodegeneration in an in vitro human blood-brain barrier model. Nanotoxicology. 2019 Feb 7;13(2):221-39.
18. Tăbăran AF, Matea CT, Mocan T, Tăbăran A, Mihaiu M, Iancu C, Mocan L. Silver nanoparticles for the therapy of tuberculosis. International journal of nanomedicine. 2020 Mar 31:2231-58.
19. Lashkari A, Ranjbar R. Nanoparticles and nanoformulated drugs as promising delivery system in treatment of microbial-induced CNS infection: a systematic review of literature. J Neurovirol. 2021 July 5;27(4):542–549.
20. Kumthekar P, Glicksman M, Schwartz M, Nagpal S, Glitza I, Forsyth P, Ruiz E, Sonabend A. Dynamic control of cerebrospinal fluid to achieve personalized drug delivery in the central nervous system. Cancer Research. 2025 Apr 21;85(8_Supplement_1):1784-.
21. Mahapatra DK, Bharti SK. Recent Advances in Bioorganism-Mediated Green Synthesis of Silver Nanoparticles: A Way Ahead for Nanomedicine. In Apple Academic; 2019. p. 275–289.
22. Rani K. Brief review on recent outcomes of applications of green synthesis vs chemical synthesis of silver nanoparticles. IJCAAP. 2020 Mar 15;5(1):9–13.
23. Kaya M, Akda\\U015F\\Xe7I E, Eker F, Bechelany M, Karav S. Silver Nanoparticles and Neurotoxicity: Mechanistic Insights and Recent Experimental Evidence. Pharmaceutics. 2026 Apr 29;18(5).
24. Kanthikeel SP, Pallikkuth S, Valiathan R, Sharma AK, George VK. Immune System of the Brain. In: Immunology. Wiley-blackwell; 2019. p. 3–16.
25. Mucke L, Eddleston M. Astrocytes in infectious and immune-mediated diseases of the central nervous system. The FASEB Journal. 1993 Oct 1;7(13):1226–1232.
26. Lee SJ. Toll-Like Receptors and Neuroinflammation. In Springer New York; 2013. p. 135–156.
27. Pascual M, Calvo‐Rodriguez M, Núñez L, Villalobos C, Ureña J, Guerri C. Toll-like receptors in neuroinflammation, neurodegeneration, and alcohol-induced brain damage. IUBMB Life. 2021 June 4;73(7):900–915.
28. Majerova P, Kovac A. Pathophysiology of the Blood–Brain Barrier in Neuroinflammatory Diseases. In Springer; 2017. p. 61–79.
29. Galea I. The blood\\u2013brain barrier in systemic infection and inflammation. Cell Mol Immunol. 2021 Sept 30;18(11):2489–2501.
30. Gorji A. Neuroinflammation: The Pathogenic Mechanism of Neurological Disorders. IJMS. 2022 May 20;23(10):5744.
31. Deus MDS, Silva MA, Alpino PKR, Ono JYT, Cassioti MCC, Camargo MLL, Santos JF, Silva LFS, Nunes RAS, Figueiredo EGS. Epidemiological profile of patients with neurotuberculosis in Brazil over the last 5 years. In: Arquivos de Neuro-Psiquiatria. 2024;82(Suppl 1):205. doi:10.5327/CBN240724.
32. Yazici O, Turgut AT, Turgut M. In Vitro and Animal Models of Tuberculosis of the Nervous System. In Springer; 2017. p. 553–559.
33. Davis AG, Rohlwink UK, Proust A, Figaji AA, Wilkinson RJ. The pathogenesis of tuberculous meningitis. Journal of Leukocyte Biology. 2019 Jan 15;105(2):267–280.
34. Hussain M, Barman B, Jamil M, Hynniewta Y. Neurotuberculosis: A mystery seeking it’s answers in pulmonary tuberculosis. Indian Journal of Tuberculosis. 2023 May 1;71(1):73–78.
35. Francisco NM, Hsu NJ, Keeton R, Randall P, Sebesho B, Allie N, Govender D, Quesniaux V, Ryffel B, Kellaway L, Jacobs M. TNF-dependent regulation and activation of innate immune cells are essential for host protection against cerebral tuberculosis. Journal of neuroinflammation. 2015 Jun 26;12(1):125.
36. Lu HJ, Guo D, Wei QQ. Potential of Neuroinflammation-Modulating Strategies in Tuberculous Meningitis: Targeting Microglia. Aging and disease. 2023 Jan 1;15(3):0.
37. Latham AS, Geer CE, Ackart DF, Weninger KN, Gross CC, Podell BK, Basaraba RJ, Moreno JA. Immune cell infiltration and modulation of the blood-brain barrier in a guinea pig model of tuberculosis: Observations without evidence of bacterial dissemination to the brain. PLoS One. 2024 Dec 31;19(12):e0307577.
38. Madadi AK, Sohn MJ. Comprehensive Therapeutic Approaches to Tuberculous Meningitis: Pharmacokinetics, Combined Dosing, and Advanced Intrathecal Therapies. Pharmaceutics. 2024 Apr 14;16(4):540.
39. Furr M. Cerebrospinal Fluid and the Blood–Brain Barrier. Wiley; 2015. p. 21–35.
40. Enikov ET, Anton R, Mack D. Smart External Ventricular Drain. In American Society Of Mechanical Engineers; 2025.
41. 12 Cerebrospinal Fluid Dynamics and Pathology. In Georg Thieme; 2017.
42. Mashayekhi F, Salehi Z. The essential role of cerebrospinal fluid in the brain; a comprehensive review. Reviews in the neurosciences. 2025 Feb 5;36(5):537–544.
43. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Progress in drug research Fortschritte der Arzneimittelforschung Progres des recherches pharmaceutiques. 2003 Jan 1;61:39–78.
44. Engelhardt B, Sorokin L. The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol. 2009 Sept 25;31(4):497–511.
45. Nag S. Morphology and molecular properties of cellular components of normal cerebral vessels. Methods in molecular medicine. 2003 Jan 1;89:3–36.
46. Jiao Y, Yang L, Wang R, Song G, Fu J, Wang J, Gao N, Wang H. Drug delivery across the blood–brain barrier: a new strategy for the treatment of neurological diseases. Pharmaceutics. 2024 Dec 19;16(12):1611.
47. Cliver RN, Ayers B, Brady A, Firestein BL, Vazquez M. Cerebrospinal fluid replacement solutions promote neuroglia migratory behaviors and spinal explant outgrowth in microfluidic culture. J Tissue Eng Regen Med. 2020 Dec 15;15(2):176–188.
48. Lepennetier G, Hracsko Z, Unger M, Van Griensven M, Grummel V, Krumbholz M, Berthele A, Hemmer B, Kowarik MC. Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. Journal of neuroinflammation. 2019 Nov 14;16(1):219.
49. Tartaglione T, Di Lella GM, Cerase A, Leone A, Moschini M, Colosimo C. Diagnostic imaging of neurotuberculosis. Rays. 1998 Feb 1;23(1):164–80.
50. Papich MG. Drug therapy for diseases of the central nervous system. In British Small Animal Veterinary Association; 2013. p. 452–469.
51. Pingle SC, Lin F, Anekoji MS, Patro CP, Datta S, Jones LD, Kesari S, Ashili S. Exploring the role of cerebrospinal fluid as analyte in neurologic disorders. Future Science OA. 2023 Apr 1;9(4):FSO851.
52. Kumar V, Gill KD. Analysis of Cerebrospinal Fluid for Proteins and Sugars. In Springer Singapore; 2018. p. 135–137.
53. Wichmann TO, Damkier HH, Pedersen M. A Brief Overview of the Cerebrospinal Fluid System and Its Implications for Brain and Spinal Cord Diseases. Front Hum Neurosci. 2022 Jan 21;15:737217.
54. Sharma A, Lakra A. Nanotechnological Advances in the Delivery of CNS Therapeutics. In Crc; 2025. p. 61–77.
55. Navarro-Flores A, Fernandez-Chinguel JE, Pacheco-Barrios N, Soriano-Moreno DR, Pacheco-Barrios K. Global morbidity and mortality of central nervous system tuberculosis: a systematic review and meta-analysis. J Neurol. 2022 Mar 15;269(7):3482–3494.
56. Seddon JA, Chow FC, Upton CM, Jain SK, Alffenaar JW, Grint DJ, Dooley K, Aarnoutse R, Cresswell FV. Intensified treatment of tuberculous meningitis in adults: A systematic review and meta-analysis.
57. (6709967) C, (4742586) A, (6709970) B. Table_1.xlsx. Figshare. 2019 May 17;
58. Bose D, Mondal A, Saha P, Seth R, Sullivan K, Janulewicz P, Horner R, Klimas N, Chatterjee S. Prolonged Antibiotic Use Worsens Neuroinflammation and Increases the Risk of Neurodegeneration via Elevated Expression of Systemic IL‐6 in Gulf War Illness Symptom Persistence Murine Model. The FASEB Journal. 2021 May;35.
59. P K, B S. A Review on Tuberculosis. IJARSCT. 2025 Nov 3;289–304.
60. Ciobanu N, Codreanu A, Turcan N, Noroc E, Crudu V. Levels of phenotypic resistance and the pattern of gene mutations of M. tuberculosis. BulMed. 2021 May 1;69(1).
61. Datta D, Jamwal S, Jyoti N, Patnaik S, Kumar D. Actionable mechanisms of drug tolerance and resistance in Mycobacterium tuberculosis. The FEBS Journal. 2024 Apr 27;291(20):4433–4452.
62. Gump WC, Summers LE, Walsh JW. Tuberculosis infection presenting as brain abscess in an immunocompromised host. The Journal of the Louisiana State Medical Society. 2006 Nov 1;158(6):292–5.
63. Takeshita Y. Antibiotic Penetration into the Central Nervous System: Decoding the Blood: Brain Barrier and Antibiotics through “Structure” to Inform Therapeutic Strategy. Brain and nerve = Shinkei kenkyu no shinpo. 2026 May 1;78(5).
64. Nau R, SöRgel F, Eiffert H. Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections. Clin Microbiol Rev. 2010 Oct 1;23(4):858–883.
65. Cepreganova Cangovska T, Zdravkov I, Aleksovska A, Ristic-Stomnaroska D, Joveva E. CENTRAL NERVOUS SYSTEM TUBERCULOSIS- CASE REPORT CASE REPORT. JMS. 2023 Jan 1;6(2):104–108.
66. Wijdicks EFM, Clark SL. Antimicrobial Therapy for Central Nervous System Infections. Oxford University; 2018.
67. Egorova EM, Krupina NA, Kaba SI, Khlebnikova NN, Shirenova SD, Sviridkina NB, Paltsyn AA. The Effect of Aqueous Solution of Silver Nanoparticles on Rat Behavior. Nanobiotechnology Reports. 2022 Apr;17(2):248-60.
68. Mohammed PN, Hussen NH, Hasan AH, Salh HJ, Jamalis J, Ahmed S, Bhat AR, Kamal MA. A review on the role of nanoparticles for targeted brain drug delivery: synthesis, characterization, and applications. EXCLI journal. 2025 Jan 3;24:34.
69. Veer B, Prajapati S, Singh AP, Yadav S. Green Synthesis of Nanoparticles: Sustainable Solutions for Multisectoral Applications. RAFNA. 2025 Sept 18;17.
70. Kameswaran S, Ramesh B, Gopal NO, Sivashankar Reddy A. Plant-Based Nanoparticle Synthesis. In Crc; 2025. p. 20–29.
71. Fu L. Pathways to Green Nanomaterials: Plants as Raw Materials, Reducing Agents and Hosts. Bentham Science; 2023 July.
72. Wickramarachchi PASR, Paragodaarachchi YL. A Review on Plant Mediated Synthesis of Silver Nanoparticles as a Greener Approach. Kalyani: J Univ Kelaniya. 2021 Dec 31;33–68.
73. Fahim M, Shahzaib A, Nishat N, Jahan A, Bhat TA, Inam A. Green synthesis of silver nanoparticles: A comprehensive review of methods, influencing factors, and applications. JCIS Open. 2024 Oct 10;16:100125.
74. Mishra V, Nayak P, Singh M, Tambuwala MM, Aljabali AA, Chellappan DK, Dua K. Pharmaceutical aspects of green synthesized silver nanoparticles: A boon to cancer treatment. Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents). 2021 Aug 1;21(12):1490-509.
75. Chopra D, Gulati M, Saluja V, Pathak P, Bansal P. Brain Permeable Nanoparticles. RPCN. 2008 Nov 1;3(3):216–225.
76. Zhang TT, Li W, Meng G, Wang P, Liao W. Strategies for transporting nanoparticles across the blood-brain barrier. Biomater Sci. 2016 Jan 1;4(2):219–229.
77. Asif N, Fatma T. Silver nanoparticles in biomedicine: green synthesis, precision theranostics, and future clinical translation. Folia microbiologica. 2026 June 4;
78. Burdușel AC, Gherasim O, Grumezescu AM, Mogoantă L, Ficai A, Andronescu E. Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview. Nanomaterials. 2018 Aug 31;8(9):681.
79. Nafady MH, Emran TB, Singh LP, Suchitra D, Haque MA, Joshi N, Parmar AB, Al Amin M, Shahriar SS, Nainu F. Investigating Potential Therapeutics for Bacterial and Cancerous Diseases: Silver Nanoparticles as a Choice.
80. Magadum P, Salve P, Khatib N. Biogenic Silver Nanoparticles from Ipomoea cairica Leaf Extract: Synthesis, Characterization, Anti‐Inflammatory Activity, and Cytotoxicity Assessment. ChemistrySelect. 2025 Nov 1;10(42).
81. Strużyńska L, Skalska J. Mechanisms Underlying Neurotoxicity of Silver Nanoparticles. Advances in experimental medicine and biology. 2018 Jan 1;1048:227–250.
82. Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016 Jan 22;15(4):275–292.
83. Bamal D, Singh A, Chaudhary G, Kumar M, Singh M, Rani N, Mundlia P, Sehrawat AR. Silver nanoparticles biosynthesis, characterization, antimicrobial activities, applications, cytotoxicity and safety issues: An updated review. Nanomaterials. 2021 Aug 17;11(8):2086.
84. K Karunakar K, Cheriyan BV, R K, M G, B A. Therapeutic advancements in nanomedicine: The multifaceted roles of silver nanoparticles. Biotechnology Notes. 2024 Jan 1;5(1):64–79.
85. Davies CDL, Snipstad S. Drug Delivery Using Nanocarriers. Wiley; 2025. p. 399–426.
86. Cramer S, Rempe R, Galla HJ. Exploiting the Properties of Biomolecules for Brain Targeting of Nanoparticulate Systems. CMC. 2012 May 1;19(19):3163–3187.
87. Pinheiro RGR, Coutinho AJ, Pinheiro M, Neves AR. Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? IJMS. 2021 Oct 28;22(21):11654.
88. Kumthekar P, Glicksman M, Schwartz M, Nagpal S, Glitza I, Forsyth P, Ruiz E, Sonabend A. Dynamic control of cerebrospinal fluid to achieve personalized drug delivery in the central nervous system. Cancer Research. 2025 Apr 21;85(8_Supplement_1):1784-.
89. (333280) N, (2883320) J, (2883332) S. Neural Cell Membrane-Coated Nanoparticles for Targeted and Enhanced Uptake by Central Nervous System Cells. Figshare. 2021 Nov 18;
90. Pandey A, Malek V, Prabhakar V, Kulkarni Y, Gaikwad A. Nanoparticles: A Neurotoxicological Perspective. CNSNDDT. 2015 Nov 27;14(10):1317–1327.
91. Spanos JP, Hsu NJ, Jacobs M. Microglia are crucial regulators of neuro-immunity during central nervous system tuberculosis. Front Cell Neurosci. 2015 May 18;9.
92. Ijaz S, Iqbal J, Abbasi BA, Yaseen T, Ashraf Z, Iqbal R, Murtaza G, Mahmood T, Kazi M. Biomedical application of green nanoparticles: insights into the anti-inflammatory molecular mechanisms. Expanding Nanobiotechnology: Applications and Commercialization. 2025 Jan 30:182-211.
93. Shenava A, Sharma S, Shetty V, Shenoy S. Silver nanoparticles: A boon in clinical medicine. J Oral Res Rev. 2015 Jan 1;7(1):35.
94. Chabuk SK, Naji RJ, Mohammed LH, Al-Fahham AA. Updates for Silver Nanoparticles’ Applications in Medical Field: A Review Article. ijmsdh. 2025 June 16;11(06):41–47.
95. Pawar AB, Korde SK, Rakshe DS, William P, Jawale MA, Deshpande N. Analysis of Silver Nanoparticles as Carriers of Drug Delivery System. J Nano- Electron Phys. 2023 Jan 1;15(4):04015–5.
96. Kumari P, Quadri K, Kadian R, Mishra S, Waziri A, Jumle K, Verma KS, Alam MS. New approaches of green silver nanoparticles for cancer and biomedical applications: a review. Exploration of Targeted Anti-tumor Therapy. 2025 Oct 23;6:1002341.
97. Nathan C, Cunningham-Bussel A. Beyond oxidative stress: an immunologist’s guide to reactive oxygen species. Nat Rev Immunol. 2013 Apr 25;13(5):349–361.
98. Jenab A, Roghanian R, Emtiazi G. Bacterial Natural Compounds with Anti-Inflammatory and Immunomodulatory Properties (Mini Review). DDDT. 2020 Sept 18;14(5):3787–3801.
99. Pandey R. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. Journal of Antimicrobial Chemotherapy. 2006 Apr 4;57(6):1146–1152.
100. Nair S, Ansari A, Khan S, Pratap A, Mali SN. Anti-inflammatory activity of Silver Nanoparticles (AgNPs): An Updated Systematic review from in vivo, and in vitro studies. Inflammopharmacol. 2026 Feb 26;34(4).
101. Murphy A, Casey A, Byrne G, Chambers G, Howe O. Silver nanoparticles induce pro-inflammatory gene expression and inflammasome activation in human monocytes. J of Applied Toxicology. 2016 Mar 10;36(10):1311–1320.
102. Freitas M, Ribeiro D, Silva P, Lima JLFC, Carvalho F, Fernandes E. Pro-inflammatory and toxic effects of silver nanoparticles. In Jenny Stanford; 2018. p. 505–530.
103. Lemus‐de la Cruz J, Landa‐Moreno CI, Trejo‐Hurtado M, Peña‐Montes DJ, Salgado‐Garciglia R, Manzo‐Avalos S, Cortés‐Rojo C, Montoya‐Pérez R, Saavedra‐Molina A. Evaluation of the antioxidant effects of green synthesis silver nanoparticles on brain from rats with experimental diabetes. The FASEB Journal. 2022 May;36.
104. El Feel E, Zaki H, Saeed H. Exploring the Toxicological Effects of Silver Nanoparticles: Oxidative Stress and Neurodegenerative Disorders. Future Perspectives of Medical, Pharmaceutical and Environmental Biotechnology. 2024 Oct 1;1(3):15–29.
105. Sadhu S, Karmakar T, Chatterjee AG, Kumari U, Mondal P, Sarkar S, Sur T, Tarafdar S. Determination of the antagonistic efficacy of silver nanoparticles against two major strains of Mycobacterium tuberculosis. Int. J. Exp. Res. Rev. 2022;29:1-9.
106. Vazquez-Muñoz R, Meza-Villezcas A, Fournier PG, Soria-Castro E, Juarez-Moreno K, Gallego-Hernández AL, Bogdanchikova N, Vazquez-Duhalt R, Huerta-Saquero A. Enhancement of antibiotics antimicrobial activity due to the silver nanoparticles impact on the cell membrane. PloS one. 2019 Nov 8;14(11):e0224904.
107. Cao H. Toward Selectively Toxic Silver Nanoparticles. In Crc; 2017. p. 301–358.
108. Duval RE, Gouyau J, Lamouroux E. Limitations of Recent Studies Dealing with the Antibacterial Properties of Silver Nanoparticles: Fact and Opinion. Nanomaterials. 2019 Dec 13;9(12):1775.
109. De Matteis V, Martano S, Pellegrino P, Ingrosso C, Costa D, Mazzotta S, Toca‐Herrera JL, Rinaldi R, Cascione M. Green silver nanoparticles: Prospective nanotools against neurodegenerative cell line model. ibrain. 2024 Jun;10(2):123-33.
110. Askari S, Eskandari M. Neurotoxicity and Biosafety of Nanomaterials. In Igi Global; 2024. p. 1–26.
111. Dhoundiyal S. Potential of Biomaterials in Advancing Neuroprotection. CMS. 2025 Sept 1;18(5):649–668.
112. Persidsky Y, Ramirez SH. Blood-Brain Barrier During Neuroinflammation. In Oxford University; 2011. p. 220–230.
113. Gelen V, Özkanlar S, Kara A, Yeşildağ A. Citrate-coated silver nanoparticles loaded with agomelatine provide neuronal therapy in acute cerebral ischemia/reperfusion of rats by inhibiting the oxidative stress, endoplasmic reticulum stress, and P2X7 receptor-mediated inflammasome. Environmental Toxicology. 2023 Nov 27;39(3):1531–1543.
114. Sharma HS, Hussain S, Schlager J, Ali SF, Sharma A. Influence of Nanoparticles on Blood–Brain Barrier Permeability and Brain Edema Formation in Rats. In Springer Vienna; 2009. p. 359–364.
115. Sonar SA, Lal G. Blood-brain barrier and its function during inflammation and autoimmunity. Journal of Leukocyte Biology. 2018 Feb 12;103(5):839–853.
116. Safari M, Bidgoli S, Rezayat S. Differential neurotoxic effects of silver nanoparticles: A review with special emphasis on potential biomarkers. Nanomedicine Journal. 2016 Apr 1;3(2).
117. Banu A, Rathod V. Biosynthesis of monodispersed silver nanoparticles and their activity against Mycobacterium tuberculosis. IJBNN. 2013 Jan 1;3(1/2):211.
118. Kiria N, Avaliani T, Bablishvili N, Phichkhaia G, Kiria N. Study of the inhibitory effect of Silver Nanoparticles on Extensively Drug-resistant Mycobacterium Tuberculosis (TB) strains. DAVID AGHMASHENEBELI UNIVERSITY OF GEORGIA SCIENTIFIC JOURNAL „SPECTRI“. 2024 July 10;
119. Gonzalez-Carter DA, Leo BF, Ruenraroengsak P, Chen S, Goode AE, Theodorou IG, Chung KF, Carzaniga R, Shaffer MS, Dexter DT, Ryan MP. Silver nanoparticles reduce brain inflammation and related neurotoxicity through induction of H2S-synthesizing enzymes. Scientific reports. 2017 Mar 2;7(1):42871.
120. Zhang W, Zhai M, Wu M, Yuan Y, Su X, Yang M, Ba Y, Deng Q, Zhang Y, Han L, Gao L. Endoplasmic Reticulum Stress and NLRP3 Inflammasome Activation Underlie Silver Nanoparticles‐Induced Neurologic Deficits in Adult Mice. Journal of Biochemical and Molecular Toxicology. 2025 Jun;39(6):e70289.
121. Hu S, Sheng WS, Peterson PK, Chao CC. Cytokine modulation of murine microglial cell superoxide production. Glia. 1995 Jan 1;13(1):45–50.
122. Barua N, Buragohain AK. Therapeutic Potential of Silver Nanoparticles (AgNPs) as an Antimycobacterial Agent: A Comprehensive Review. Antibiotics. 2024 Nov 20;13(11):1106.
123. Raza M, Lee HY. Review on Harnessing Silver Nanoparticles for Therapeutic Innovations: A Comprehensive Review on Medical Applications, Safety, and Future Directions. CTMC. 2025 Oct 20;26.
124. Laib I, Gheraissa N, Benaissa A, Benkhira L, Azzi M, Benaissa Y, Abdelaziz AG, Tian F, Walsh M, Bechelany M, Barhoum A. Tailoring innovative silver nanoparticles for modern medicine: The importance of size and shape control and functional modifications. Materials Today Bio. 2025 Aug 1;33:102071.
125. Zaharov AV, Khokhlov AL, Ergeshov AE. SILVER NANOPARTICLES IN THE SOLUTION OF THE PROBLEM OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS. Arhivʺ vnutr med. 2017 Jan 1;7(3):188–199.
126. Xu F, Piett C, Farkas S, Qazzaz M, Syed NI. Silver nanoparticles (AgNPs) cause degeneration of cytoskeleton and disrupt synaptic machinery of cultured cortical neurons. Mol Brain. 2013 Jan 1;6(5):29.
127. Hussain S. Nanoparticles as Antituberculosis Drugs: A review. mmsj. 2014 Dec 31;1(1):64–75.
128. Đorđević S, Gonzalez MM, Conejos-Sánchez I, Carreira B, Pozzi S, Acúrcio RC, Satchi-Fainaro R, Florindo HF, Vicent MJ. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug delivery and translational research. 2022 Mar;12(3):500-25.
129. Hasan SM, Hussain S, Yousuf M, Tapia-Hernández JA, Raja DA. Protein-Based Silver Nanoparticles: Synthesis, Characterization, Administration, and Nanomedicine Applications. International Journal of Biomaterials. 2025 Jan 1;2025(3):5533798.
130. Iqbal A, Ahmad I, Khalid MH, Nawaz MS, Gan SH, Kamal MA. Nanoneurotoxicity to Nanoneuroprotection Using Biological and Computational Approaches. Journal of Environmental Science and Health, Part C. 2013 Jan 1;31(3):256–284.
131. Wang J, Sun W, Ali SF. Nanoparticles: Is Neurotoxicity a Concern? Wiley; 2009. p. 171–182.
132. Shiraz M, Imtiaz H, Azam A, Hayat S. Phytogenic nanoparticles: synthesis, characterization, and their roles in physiology and biochemistry of plants. Biometals. 2023 Nov 2;37(1):23–70.
133. (7375874) P, (7375877) A, (23227) A. DataSheet_1.pdf. Figshare. 2019 Sept 12;
134. Patel P, Kumari P, K Verma S, Mallick MA. Cellular and Molecular Impact of Green Synthesized Silver Nanoparticles. In Intechopen; 2020.
135. Dias M, Zhang R, Lammers T, Pallares RM. Clinical translation and landscape of silver nanoparticles. Drug Deliv and Transl Res. 2024 Oct 8;15(3):789–797.
136. – P, – M, – J, – A. Unveiling Biological Synthesis of Metal Nanoparticles, their Characterization and Scopes : A Review. IJFMR. 2023 July 6;5(4).
137. Jain K, Takuli A, Gupta TK, Gupta D. Rethinking Nanoparticle Synthesis: A Sustainable Approach vs. Traditional Methods. Chemistry An Asian Journal. 2024 Oct 3;19(21):e202400701.
138. Dove A. Uncorking the biomanufacturing bottleneck. Nat Biotechnol. 2002 Aug 1;20(8):777–779.
139. Ramos TI, Villacis-Aguirre CA, López-Aguilar KV, Santiago Padilla L, Altamirano C, Toledo JR, Santiago Vispo N. The Hitchhiker’s guide to human therapeutic nanoparticle development. Pharmaceutics. 2022 Jan 21;14(2):247.
140. Yundt-Pacheco J, Parvin CA. The impact of QC frequency on patient results. MLO: medical laboratory observer. 2008 Sept 1;40(9):24–27.
141. Sair YZ, Ashraf H, Ghafoor MBA, Shanza, Shabbir M, Ali Z, Khan A, Yasin M, Iftikhar M. Eco-Innovations in Nanoscience: Advances in Sustainable Synthesis and Physico-Chemical Characterization of Silver Nanoparticles and their Bio Medical Applications. Sch Acad J Biosci. 2025;13(6):674-686. doi:10.36347/sajb.2025.v13i06.005.
142. Barkat MA, Harshita, Beg S, Naim MJ, Pottoo FH, Singh SP, Ahmad FJ. Current progress in synthesis, characterization and applications of silver nanoparticles: precepts and prospects. Recent Patents on Anti-Infective Drug Discovery. 2018 Apr 1;13(1):53-69.
143. Li Y, Cummins E. Hazard characterization of silver nanoparticles for human exposure routes. Journal of Environmental Science and Health, Part A. 2020 Mar 13;55(6):704–725.
144. Huynh‐Ba K. Good Manufacturing Practices (GMPs) and the Quality Systems. Wiley; 2022. p. 26–56.
145. Wang C. Enhancing Scientific Rigor in Basic Nanomedicine Research for Improved Clinical Translation. AJBSR. 2024 Jan 10;21(1):84–86.
146. Saleh A, Asfuroğlu E, Güngördü B, Bağcı C. Green-Synthesized Silver Nanoparticles and the Effect on Human Neuroblastoma Cells. In Institute Of Electrical Electronics Engineers; 2024. p. 1–4.
147. Jefferson F, Dean K. Silver Nanoparticles: Neurotoxic and Neurodegenerative Effects. ISCTJ. 2016 Oct 4;02(10).
148. Ren Y, Zhang Y, Li X. Application of AgNPs in biomedicine: An overview and current trends. Nanotechnology Reviews. 2024 July 1;13(1).
149. Jothilakshmi R, Srinivasan R. Development and characterization of polyherbal silver nanoparticles from Lepidagathis species for targeted neuroinflammation therapy. Plant Sci Today. 2025 July 7;
150. Angelova A, Angelov B, Lesieur S. Designing nanoparticles for delivery of neurotrophic proteins. Mol Neurodegeneration. 2013 Sept 1;8(Suppl 1).
151. Zhang ZQ, Meng C, Hou K, Wang ZG, Huang Y, Lü XY. The cytological and electrophysiological effects of silver nanoparticles on neuron-like PC12 cells. Research Square. American Journal Experts; 2022.
152. Prakash PJ, Royana S, Sankarsan P, Rajeev S. The Review of Small Size Silver Nanoparticle Neurotoxicity: A Repeat Study. J Cytol Histol. 2017 Jan 1;08(03).
153. Kapoor DU, Sharma JB, Gandhi SM, Prajapati BG, Thanawuth K, Limmatvapirat S, Sriamornsak P. AI-driven design and optimization of nanoparticle-based drug delivery systems. Science, Engineering and Health Studies. 2024 Dec 6:24010003-.
154. Mamgain A, Parveen N, Kenwat R, Shukla R, Paliwal SR, Paliwal R. Green Synthesis of Nanoparticles. In Crc; 2024. p. 352–365.
155. Williams E, Smith R, Bora A, Spitzer N. Silver nanoparticle-induced disruption of the tripartite synapse in rat brain. Proc W Va Acad Sci. 2025 Apr 4;97(2).